MACROGENICS INC (MGNX)
Health Care · Clinical-stage immunotherapy and ADC biopharmaceuticals · NASDAQ
Clinical-stage biopharmaceutical company developing innovative antibody-based cancer therapeutics using proprietary DART, TRIDENT, and ADC platforms.
What MACROGENICS INC does
MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer treatment. The company generates its pipeline from proprietary technology platforms including antibody-drug conjugates (ADCs) and multi-specific antibodies (DART and TRIDENT molecules). It has three proprietary product candidates in clinical development and three FDA-approved products for which it retains economic rights. The company also operates a commercial-scale cGMP antibody manufacturing facility that provides contract development and manufacturing services to offset facility costs.
Themes: ["Immuno-oncology / cancer immunotherapy","Antibody engineering","ADC (antibody-drug conjugate) development","Multi-specific antibodies","Checkpoint inhibitor combinations","Solid tumor oncology","Contract manufacturing / CDMO services"]
Fundamentals
- Price$4.57 as of 2026-07-09 close
- Market cap$296M as of 2026-07-10
- 1-year return+187.4% as of 2026-07-09 close
- Net margin-44.8% as of 2026-07-10
- Gross margin+74.5% as of 2026-07-10
- ROE-147.8% as of 2026-07-10
- Debt / equity3.24 as of 2026-07-10
- Revenue growth (YoY)+2.0% as of 2026-07-10
- Revenue CAGR (3y)-0.5% SEC XBRL
- Beta1.19 as of 2026-07-10
Key risks (from latest filing)
["Dependence on successful outcomes of ongoing and planned clinical trials; delays or negative data could impact regulatory approvals and commercialization timelines.","Ability to obtain and maintain FDA regulatory approvals for product candidates is uncertain, and unfavorable labeling or approval denials could significantly impact commercial prospects.","Ongoing operating losses and need to raise additional capital through financings, collaborations, or asset sales; sale of CDMO operations is pending and critical to liquidity management."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.